Treatment-resistant depression

MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Pharmaceutical, Health, Clinical trials, Branches of biology, Ionotropic glutamate receptors, Life sciences, Biology, NMDA receptor antagonists, GRIN2B, Major depressive disorder, Novartis, NMDA receptor, Mij, Treatment-resistant depression

MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.

Key Points: 
  • MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.
  • "MIJ 821 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Treatment Resistant Depression are giving market competition to MIJ 821 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Epidemiology Forecast on Treatment-resistant Depression to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 4, 2020
Hospitals, General Health, Health, Mental health, Medicine, Articles, Drug resistance, Treatment-resistant depression, TRD, Major depressive disorder, Epidemiology, Health sciences, Disease

The "Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Treatment-resistant depression epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant depression epidemiology segmented as the Total diagnosed Prevalent of Treatment-resistant depression, Gender-specific cases, Age-specific cases.
  • Quantify patient populations in the global Treatment-resistant depression (TRD) market to improve product design, pricing, and launch plans
    The Treatment-resistant depression (TRD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
    The Treatment-resistant depression (TRD) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.

The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited to Develop Novel Treatment for Patients with Diverse Psychiatric Disorders

Retrieved on: 
Friday, October 30, 2020
Mental health, Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Psychiatry, Psychiatric diagnosis, Psychology, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Treatment-resistant depression, Rugen Therapeutics, McQuade Center for Strategic Research and Development (MSRD), Otsuka

The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD).

Key Points: 
  • The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD).
  • Rugens proprietary technology stems from its novel research into the circuit mechanisms of psychiatric disorders, facilitated by genetic-based animal models.
  • This research has translated into its innovative drug candidate, which has potentially broad application across multiple psychiatric indications.
  • Rugen Holdings (Cayman) Limited, dba Rugen Therapeutics is a biotech company discovering and developing novel, first-in-class, small-molecule drugs with the potential to address multiple psychiatric indications.

Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder

Retrieved on: 
Tuesday, October 13, 2020
Major depressive disorder, Branches of biology, Mood disorders, Abnormal psychology, Treatment-resistant depression, Antidepressant, Transcranial magnetic stimulation, Management of depression, Todd M. Hutton

The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive option for treating depression.

Key Points: 
  • The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive option for treating depression.
  • The study authors found that treatment with NeuroStar Advanced Therapy showed robust antidepressant effects, greater than in early open-label studies of transcranial magnetic stimulation (TMS).
  • The clinical benefit from NeuroStar Advanced Therapy reported by both patients and clinicians in routine clinical practice compared favorably with alternative interventions for treatment-resistant depression.
  • The authors analyzed two sample sets of more than 5,000 patients across 103 practice sites, evaluating patient-rated and clinician-rated clinical outcomes data from treatment with NeuroStar.

Dr. Ashraf Hanna's Innovative Ketamine Protocol Delivers a Complete Sustained Remission in a Patient with Depression and Suicidal Ideation

Retrieved on: 
Tuesday, October 6, 2020
Drugs, Psychoactive drugs, RTT, Branches of biology, Psychiatric diagnosis, Antidepressants, Amines, Ketamine, Treatment-resistant depression, Post-traumatic stress disorder, Selective serotonin reuptake inhibitor, Obsessive–compulsive disorder

Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.

Key Points: 
  • Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.
  • IV Ketamine therapy is only reserved for those patients that have treatment-resistant depression and have failed conventional therapy.
  • I then wanted to expand the treatment for PTSD, depression, bipolar depression and obsessive compulsive disorders.
  • For more information regarding IV Ketamine Infusion therapy for Depression and PTSD , please visit: https://www.ivketamine.com orcall 727-538-2646

Nexstim Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus® rTMS Treatment of Major Depressive Disorder

Retrieved on: 
Monday, October 5, 2020
Branches of biology, Neurotechnology, Neuroscience, Medicine, Treatment of bipolar disorder, Treatment of depression, Electrotherapy, Medical devices, Transcranial magnetic stimulation, Clinical endpoint, Treatment-resistant depression

Treatment outcomes of these 108 patients were good: 42 % were in remission at end of treatment and 74 % obtained a clinical response.

Key Points: 
  • Treatment outcomes of these 108 patients were good: 42 % were in remission at end of treatment and 74 % obtained a clinical response.
  • The clinical outcomes of majority of the patients treated with SmartFocus rTMS in the United States are being collected in a registry the information is provided by participating clinical sites using Nexstims SmartFocus technology.
  • The number of patients who are being treated with Nexstim SmartFocus rTMS is growing fast.
  • Mikko Karvinen, CEO of Nexstim, said: We are very happy to continue reporting these very promising clinical results on the use of our SmartFocus rTMS for major depressive disorder.

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29

Retrieved on: 
Wednesday, September 23, 2020
Psychiatric diagnosis, Medical specialties, Psychiatry, Mood disorders, Major depressive disorder, Management of depression, Tumor necrosis factor, Treatment-resistant depression, Clinical medicine

In addition to his medical training, Dr. Raison obtained his Masters of English from the University of Denver.

Key Points: 
  • In addition to his medical training, Dr. Raison obtained his Masters of English from the University of Denver.
  • Dr. Raison has written and published more than 100 scientific papers as well 20 review papers and editorials.
  • His visionary work focuses on the treatment of depression in response to illness and stress, translating neurobiological findings into novel interventions.
  • DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers and treatment resistant depression (XPro1595), and NASH (LIVNate).

NY Ketamine Infusions, New York City's Premier Ketamine Depression Clinic, Brings Breakthrough Treatments to Long Island

Retrieved on: 
Tuesday, September 22, 2020
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Amines, Chloroarenes, Nicotinic antagonists, Sedatives, Treatment-resistant depression, Ketamine

In multiple studies performed over the past 20 years by researchers at Yale University, Mt.

Key Points: 
  • In multiple studies performed over the past 20 years by researchers at Yale University, Mt.
  • Citing a recent study, Cleveland Clinic noted that "within 24 hours of receiving ketamine, 70 percent of patients with treatment-resistant depression saw an improvement in symptoms."
  • NY Ketamine Infusions has been helping patients who have not responded to either traditional psychiatric medications or psycho-therapyoften with tremendous, life-changing results.
  • "In our new Long Island office, we promise to provide the highest level of individualized care to each of our patients.

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression

Retrieved on: 
Wednesday, September 16, 2020
Mind, Psychiatry, Psychology, Mood disorders, Psychiatric diagnosis, Abnormal psychology, Anhedonia, Major depressive disorder, Treatment-resistant depression, Biomarker, Depression

The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression.

Key Points: 
  • The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression.
  • Treatment resistant depression is a major problem affecting more than seven million patients in the U.S. alone, said CJ Barnum Ph.D., head of neurosciences at INmune Bio.
  • This Phase 2 multi-center, blinded, randomized study will enroll patients with treatment resistant depression that have biomarkers of inflammation and anhedonia (inability to feel pleasure).
  • ET on Tuesday, September 29, 2020 to provide additional information about the role of neuroinflammation in treatment resistant depression.

Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 8, 2020
Health, Drugs, Antidepressants, Bupropion/dextromethorphan, Major depressive disorder, Psychiatric diagnosis, Treatment-resistant depression, Smoking cessation, AXS

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.

Key Points: 
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.
  • For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines.
  • Axsomes core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14.
  • AXS-05 is being developed for major depressive disorder (MDD), treatment resistant depression (TRD), Alzheimers disease (AD) agitation, and as a treatment for smoking cessation.